Global Osteogenesis Imperfecta Treatment Market - 2023-2030

Global Osteogenesis Imperfecta Treatment Market - 2023-2030

Global osteogenesis imperfecta treatment market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Osteogenesis imperfecta (OI) is also known as brittle bone disease, an inherited (genetic) bone disorder that is present at birth. A child born with OI may have soft bones that break (fracture) easily, bones that are not formed normally and other problems. Signs and symptoms may range from mild to severe. There are at least 8 different types of the disease. The types vary greatly, both within and between types. They are based on the type of inheritance and signs and symptoms.

There is no cure for osteogenesis imperfecta. Depending on the type of OI, treatment plans focus on managing symptoms, increasing bone mass and improving strength. The main goal of treatment is to prevent deformities and fractures. And, once the child gets older, allow him or her to function as independently as possible. Physical and occupational therapy is used to increase a child’s mobility and muscle strength, bisphosphonate medications are used to strengthen a child’s bones, surgery to place rods in a child’s bones and reconstructive surgery to correct bone deformities.

Market Dynamics: Drivers

Rising demand for novel therapeutics

The rising demand for novel therapeutics is expected to drive the market over the forecast period. Osteogenesis imperfecta is a rare and complex genetic disorder with varying degrees of severity. There is no cure for this condition, current treatment options focus on symptom management and fracture prevention, leaving significant unmet medical needs. There is a demand for therapies that can directly address the underlying genetic or molecular causes of osteogenesis imperfacta. So, many major market players are focusing on developing novel therapeutics that directly focus on the treatment of the condition.

For instance, on June 05, 2023, Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc released the data from the dose-selection Phase 2 portion of the Phase 2/3 Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients. Across all patients evaluated setrusumab demonstrated statistically significant increases in levels of serum P1NP, a sensitive marker of bone formation and a substantial and significant improvement in bone mineral density (BMD) by 3 months.

In addition, ongoing advancements in genetic research have provided a deeper understanding of the genetic mutations that are responsible for osteogenesis imperfecta. This knowledge has paved the way for the development of targeted therapies, including gene therapies and other precision medicine approaches. And, there is an increasing number of clinical trials for the development of novel therapeutics to address the major unmet medical needs associated with the condition.

For instance, on August 01, 2022, Quince Therapeutics, Inc. focussed on the clinical development of its highly differentiated bone-targeting drug platform and lead precision bone growth molecule, NOV004, to address major unmet medical needs across multiple skeletal therapeutic indications. Discovery pipeline positioned for rapid expansion across multiple skeletal therapeutic indications, including osteogenesis imperfecta, fractures, spinal fusion and other severe bone diseases.

Further, the increasing prevalence of osteogenesis imperfecta, increasing clinical trials to develop more advanced and novel therapies, increasing awareness about the condition and its severity and increasing advancements in the development of combination therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the surgery, side effects of various drugs, the high cost of the treatment, unmet needs and uncertainties regarding treatment are the factors expected to hamper the market.

Segment Analysis

The global osteogenesis imperfecta treatment market is segmented based on disease type, treatment type, route of administration, end-user and region.

The bisphosphonate medicines segment accounted for approximately 58.5% of the osteogenesis imperfecta treatment market share

The bisphosphonate medicines segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for osteogenesis imperfecta. Bisphosphonates are potent anti-resorptive agents that inhibit osteoclast function. All bisphosphonate compounds have a backbone that resembles pyrophosphate, which explains the affinity of these drugs for mineralized surfaces. Importantly, all bisphosphonates are incorporated into bone mineral and remain there for many years.

Treatment with bisphosphonates is known to bring significant clinical improvements for children and adolescents suffering from moderate to severe forms of osteogenesis imperfecta (OI). Benefits include decreased pain, lower fracture incidence and better mobility. Among the various bisphosphonates, intravenous pamidronate is most commonly used. It is unclear whether oral bisphosphonates are as effective as intravenous pamidronate. As the effect of bisphosphonates on the skeleton is largest during growth, it appears logical to start medical therapy for OI patients as early as possible.

Bisphosphonates act by inactivating osteoclasts, the cells that break down bone tissue, thereby inhibiting bone resorption. There are two different types of bisphosphonates, nitrogenous and non‐nitrogenous. Nitrogenous bisphosphonates disrupt osteoclast formation, survival and cytoskeletal dynamics. Non‐nitrogenous bisphosphonates initiate osteoclast apoptosis. The bisphosphonates vary in their efficacy and absorption when taken orally, making direct comparison challenging. So, these wide benefits of biphosphonates for OI treatments helps to hold the largest market share for this segment.

Geographical Analysis

North America accounted for approximately 41.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing investments in the development of novel therapies. North America region especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. This presence of major players in the region helps to develop more advanced therapeutics for the management of this condition.

In addition, there are increasing investments in the development of novel therapies for the better management of the condition and its severity, is also helps to drive the market in the region. As the prevalence of osteogenesis imperfecta increases in the region, there is an increasing demand for therapeutics to manage the condition in the early stages. Health organizations and research institutes are focussing on research activities through increasing investments.

For instance, according to the NIH, an estimated 25,000 to 50,000 people in the United States live with OI, a rare genetic disorder of connective tissues that has no cure. And, in November 2023, a UAMS research team is using a $1.54 million grant from the National Institutes of Health (NIH) to support its goal of finding better treatments for osteogenesis imperfecta (OI), also known as brittle bone disease.

Competitive Landscape

The major global players in the osteogenesis imperfecta treatment market include Mereo BioPharma Group PLC, Ultragenyx Pharmaceutical Inc., Pfizer Inc., Merck KGaA, Bayer AG, Dr. Reddy’s Laboratories Ltd., Adooq Bioscience LLC., Teva Pharmaceutical Industries Ltd., Novartis AG and Sanofi SA among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global osteogenesis imperfecta treatment market. Although genetic diseases like osteogenesis imperfecta are rare, children with such conditions who get infected with COVID-19 tend to have a severe illness requiring hospitalization. Additionally, the pandemic temporarily disrupted the clinical trials and research activities for novel therapies. The pandemic also disrupted the global supply chain of these therapeutics.

Market Segmentation

By Disease Type
• Type I
• Type II
• Type III
• Type IV
• Type V
• Type VI
• Type VII
• Type VIII

By Treatment Type
• Bisphosphonate Medicines
• Physical Therapy
• Occupational Therapy
• Assistive Devices
• Reconstructive Surgery
• Others

By Route of Administration
• Intravenous
• Oral
• Others

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global osteogenesis imperfecta treatment market segmentation based on disease type, treatment type, route of administration, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of osteogenesis imperfecta treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global osteogenesis imperfecta treatment market report would provide approximately 69 tables, 77 figures, and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies